LungÕ 2026: Global Experts Examine the Changing Landscape of Lung Cancer Care
After a Decade Without a New Option, FDA Approves Amivantamab for Head and Neck Cancer
Solomon Moshkevich Named CEO of Natera
Timothy Rebbeck: Science Gains a Stronger Voice in the U.S. Congress
Prostate Cancer Radiotherapy: HYPO-RT-PC Study Reveals Significant Gaps Between Patient and Clinician Symptom Reporting
Can Laser Hair Removal Cause Cancer? What Science Says
SIOG 2026: 15 Posts Not to Miss from the Annual Conference in Valencia
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
